Journal of Carcinogenesis
Covering Genesis to Therapeutics
Journal of Carcinogenesis, ISSN: 1477-3163
2025; Vol 24: Issue 6s, https://carcinogenesis.com/

Optimizing Patient Outcomes: A Comprehensive Review of Oral Medication Management in Patients Undergoing Radiotherapy

Faisal Daufallah Ali Alamri[1], Salman Fahad Alotaibi[2], Musab abdulrahman alshehri[3], sami mohammed alshammari[4]

[1]Hospital name-Health center in security patrols City- Riyadh

Job title-Clinical Pharmacy

Email address-Fff.o@hotmail.com

[2]Hospital name / Health center in security patrols City / Riyadh

Job title / Specialist-Radiological Technology

Email address / s.lt23@hotmail.com

[3]Hospital name / Health center in security patrols City / Riyadh

Job title / Specialist-Radiological Technology

Email address / mus3bgas1411@gmail.com

[4]Hospital name-Health center in security patrols City- Riyadh

Job title Nursing Specialist

Email address-Sami87_@hotmail.com

ABSTRACT

Radiation therapy (RT) is a cornerstone of modern oncological treatment, employed in over 50% of cancer cases. While highly effective, it is invariably associated with a range of acute and chronic side effects that significantly impact patient quality of life (QoL) and treatment tolerance. The management of these toxicities relies heavily on pharmacological interventions, with oral medications (tablets, capsules) being the most frequently administered route due to their convenience and cost-effectiveness. This paper provides a comprehensive review of the common classes of oral medications utilized during radiotherapy, their indications, mechanisms of action, and the critical importance of managing their side effects and potential interactions. We discuss protocols for managing dermatologic, gastrointestinal, genitourinary, and pain-related toxicities. Furthermore, we emphasize the challenges of polypharmacy, patient compliance, and the necessity of a multidisciplinary approach involving radiation oncologists, pharmacists, and nurses to optimize therapeutic outcomes. The data synthesized herein underscores that effective oral medication management is not merely supportive but integral to the successful completion of radical radiotherapy regimens.

Keywords: *Radiotherapy, Oral Medication, Supportive Care, Toxicity Management, Polypharmacy, Patient Compliance, Drug Interactions.*

How to Cite: Faisal Daufallah Ali Alamri, Salman Fahad Alotaibi, Musab abdulrahman alshehri, sami mohammed alshammari., (2025) Optimizing Patient Outcomes: A Comprehensive Review of Oral Medication Management in Patients Undergoing Radiotherapy, *Journal of Carcinogenesis*, *Vol.24*, *No.6s*, 255-258.

1. INTRODUCTION

Radiation therapy utilizes high-energy radiation to kill cancer cells and shrink tumors. Despite technological advancements like Intensity-Modulated Radiotherapy (IMRT) and Image-Guided Radiotherapy (IGRT) that improve precision, exposure of surrounding healthy tissues is often unavoidable. This leads to a predictable spectrum of side effects localized to the treatment field, such as radiation dermatitis, mucositis, xerostomia, esophagitis, enteritis, cystitis, and fatigue [1].

The successful delivery of a prescribed radiation course is contingent on managing these toxicities to prevent unscheduled treatment breaks, which are known to detrimentally affect tumor control probability [2]. Oral medications form the first line of defense against these adverse effects. Their role extends beyond palliation to being proactive and reactive agents that enable dose escalation and treatment completion. This paper aims to catalog and analyze the evidence-based use of these oral agents, creating a reference for clinical practice.

2. COMMON ORAL MEDICATIONS BY INDICATION

The choice of oral medication is dictated by the site of radiation and the specific toxicity experienced by the patient.

Toxicity Medication Class Example Drugs Mechanism of Action Notes
Radiation Dermatitis Topical Corticosteroids (often creams, but systemic may be used) Mometasone furoate 0.1% cream Reduce inflammation, itching, and erythema Evidence supports prophylactic use for reducing grade 2+ dermatitis [3].

Analgesics Acetaminophen, NSAIDs (e.g., Ibuprofen) Pain relief, anti-inflammatory For mild to moderate pain and inflammation.

Oral Mucositis Analgesics (Local & Systemic) "Magic Mouthwash" (compounded), Benzocaine lozenges Topical anesthetic for pain control Temporary relief; does not heal mucositis.

Systemic Analgesics Acetaminophen, Opioids (e.g., Oxycodone) Systemic pain control For moderate to severe pain. Opioids often necessary.

Mucosal Protectants Sucralfate suspension Forms a protective barrier over ulcers Evidence is mixed; not consistently recommended [4].

Xerostomia Salivary Stimulants Pilocarpine, Cevimeline Cholinergic agonists that stimulate saliva production Used after RT; limited efficacy during active treatment if glands are within field.

Toxicity Medication Class Example Drugs Mechanism of Action Notes Nausea/Vomiting 5-HT3 Receptor Antagonists Ondansetron, Granisetron Block serotonin receptors in the GI tract and CNS First-line for radiation-induced nausea and vomiting (RINV).

Dopamine Antagonists Metoclopramide, Prochlorperazine Block dopamine D2 receptors in the chemoreceptor trigger zone Useful for less severe nausea; metoclopramide also promotes gastric emptying.

NK-1 Receptor Antagonists Aprepitant Substance P antagonist Used for high-risk emetogenic radiation.
Diarrhea Antimotility Agents Loperamide, Diphenoxylate/Atropine Slow intestinal motility and reduce secretion First-line treatment. Monitor for dehydration.

Bile Acid Sequestrants Cholestyramine Binds bile acids that can cause diarrhea after pelvic RT Second-line if loperamide fails.

Octreotide (SC/IV, but oral analogs in dev.) - Inhibits secretory diarrhea Reserved for severe, refractory cases.

Esophagitis Analgesics Lidocaine solutions, Sucralfate suspension, Systemic Opioids Topical coating and pain control Often requires opioid analgesia for swallowing.

Proton Pump Inhibitors (PPIs) Omeprazole, Pantoprazole Reduce gastric acid production Used if reflux is a component, e.g., in thoracic RT.

Symptom Medication Class Example Drugs Mechanism of Action Notes Pain (Tumor or Tx related) NSAIDs Ibuprofen, Naproxen Inhibit cyclooxygenase (COX), reducing prostaglandins. For bone pain or inflammatory pain. Caution with thrombocytopenia.

Opioids Oxycodone, Morphine SR, Hydromorphone Agonists at central and peripheral opioid receptors. Mainstay for moderate to severe cancer pain. Manage side effects (constipation, nausea).

Adjuvant Analgesics Gabapentin, Pregabalin Bind to α2δ subunit of voltage-gated calcium channels. For neuropathic pain

or shooting/burning sensations.

Anxiety/Depression SSRIs/SNRIs Sertraline, Escitalopram, Duloxetine Increase synaptic serotonin/norepinephrine. Manage adjustment disorder, depression, and may help with neuropathic pain (duloxetine).

Benzodiazepines Lorazepam Enhance GABA neurotransmission. For acute anxiety, particularly anxiety-induced nausea. Fatigue Stimulants Methylphenidate, Modafinil Increase dopamine and norepinephrine in the CNS. Second-line for severe fatigue after ruling out other causes (anemia, hypothyroidism).

3. CRITICAL CONSIDERATIONS IN MEDICATION MANAGEMENT

3.1. Polypharmacy and Drug Interactions Cancer patients often take multiple medications concurrently, including chemotherapy, supportive care drugs, and medications for comorbidities. This polypharmacy increases the risk of significant drug-drug interactions [5].

Example 1: Many opioids (e.g., oxycodone) and antiemetics (e.g., ondansetron) are metabolized by the cytochrome P450 system (CYP3A4, CYP2D6). Concurrent use with CYP inhibitors or inducers can lead to toxicity or reduced efficacy.
· Example 2: Diarrhea caused by pelvic radiation can reduce the absorption of orally administered drugs, such as analgesics or antihypertensives, rendering them less effective.

3.2. Impact of Radiotherapy on Drug Pharmacokinetics Radiation's effect on healthy tissues can alter how the body processes drugs.

- Mucositis and Malabsorption: Damage to the intestinal villi can impair the absorption of many oral medications.
- Nausea and Vomiting: This can lead to vomiting of recently ingested tablets, resulting in under-dosing.
- Hepatic and Renal Function: While less common with modern techniques, radiation to the abdomen could potentially affect liver and kidney function, organs critical for drug metabolism and excretion.

3.3. Patient Adherence and Education The complexity of medication regimens is a major barrier to adherence. Factors include:

- Pill Burden: A high number of daily tablets can be overwhelming.
- Side Effects: Patients may stop taking a medication due to its own side effects (e.g., constipation from opioids).
- Cognitive Load: Fatigue and "chemo brain" can impair a patient's ability to follow complex schedules.

Strategies for Improvement: Utilizing pill organizers, providing clear written schedules, involving family members, and using smartphone app reminders can significantly improve adherence.

4. DISCUSSION

The administration of oral medications during radiotherapy is a dynamic and complex process. It requires continuous assessment and adjustment based on the patient's evolving symptoms and treatment phase. The evidence supports a proactive rather than reactive approach for certain toxicities, such as the prophylactic use of topical steroids for dermatitis and 5-HT3 antagonists for RINV.

A major gap in current practice is the lack of universally standardized protocols for oral supportive care. Decisions are often based on institutional preference and clinician experience. Future research should focus on:

1. Developing and validating standardized evidence-based guidelines for oral supportive care stratified by radiation site.
2. Investigating the pharmacokinetics of key oral drugs in patients experiencing active radiation-induced toxicities.
3. Leveraging technology (e.g., digital health platforms) to improve medication adherence and symptom tracking in real-time.

The role of the multidisciplinary team cannot be overstated. Pharmacists are essential for reviewing medication lists for interactions and counseling patients. Nurses are on the front line, assessing symptoms and educating patients on medication

use. This collaborative approach is paramount for maximizing the safety and efficacy of oral medication regimens.

5. CONCLUSION

Oral medications are indispensable tools in the management of radiation-induced toxicities. They empower patients to tolerate and complete curative radiotherapy courses with a better quality of life. However, their use is not without challenges, including polypharmacy, potential interactions, variable absorption, and adherence issues. A meticulous, patient-centered, and multidisciplinary approach to prescribing and managing these tablets is crucial. By optimizing oral supportive care, clinicians directly contribute to improving oncological outcomes by minimizing treatment interruptions and enhancing patient well-being throughout their radiation journey.

REFERENCES

[1] Hoppe, R. T., et al. (2019). Bentley's Practical Radiotherapy & Oncology. Elsevier.
[2] Son, C. H., et al. (2017). "The impact of treatment interruptions on local control in head and neck cancer." Radiotherapy and Oncology, 123(3), 388-393.
[3] Schnur, J. B., et al. (2021). "A systematic review of randomized trials for the prevention of radiation dermatitis." Supportive Care in Cancer, 29(10), 5609-5619.
[4] Lalla, R. V., et al. (2014). "MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy." Cancer, 120(10), 1453-1461. [
[5] Popa, M. A., et al. (2014). "Polypharmacy and drug interactions in older cancer patients." Critical Reviews in Oncology/Hematology, 92(2), 105-115.